Movement Alert｜BEONE MEDICINES Drops 6.3% in Regular Trading, Trading at 209.6 HKD

Market Focus

9 hours ago

On October 2, BEONE MEDICINES fell 6.3% in regular trading, trading at 209.6 HKD/share, with turnover of approximately 105 million HKD.

Within the Biotechnology sector where BEONE MEDICINES belongs, the overall sector came under broad selling pressure. Among individual stocks, INNOVENT BIO down 5.1%, AKESO down 2.67%, SKB BIO down 4.52%, 3SBIO down 5.43%, HENLIUS down 3.32%.

BEONE MEDICINES is a global oncology company focused on developing novel therapies for cancer patients worldwide. Its product portfolio spans hematology and solid tumors, with key marketed products including Brukinsa, Tevimbra, and Pamiparib, alongside a deep pipeline of next-generation candidates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1177560204"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177560204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177560204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-02 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177560204","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Drops 6.3% in Regular Trading, Trading at 209.6 HKD","media":"Market Focus","content":"<p><p>On October 2, BEONE MEDICINES fell 6.3% in regular trading, trading at 209.6 HKD/share, with turnover of approximately 105 million HKD.</p><p>Within the Biotechnology sector where BEONE MEDICINES belongs, the overall sector came under broad selling pressure. Among individual stocks, INNOVENT BIO down 5.1%, AKESO down 2.67%, SKB BIO down 4.52%, 3SBIO down 5.43%, HENLIUS down 3.32%.</p><p>BEONE MEDICINES is a global oncology company focused on developing novel therapies for cancer patients worldwide. Its product portfolio spans hematology and solid tumors, with key marketed products including Brukinsa, Tevimbra, and Pamiparib, alongside a deep pipeline of next-generation candidates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Drops 6.3% in Regular Trading, Trading at 209.6 HKD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Drops 6.3% in Regular Trading, Trading at 209.6 HKD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-02 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 2, BEONE MEDICINES fell 6.3% in regular trading, trading at 209.6 HKD/share, with turnover of approximately 105 million HKD.</p><p>Within the Biotechnology sector where BEONE MEDICINES belongs, the overall sector came under broad selling pressure. Among individual stocks, INNOVENT BIO down 5.1%, AKESO down 2.67%, SKB BIO down 4.52%, 3SBIO down 5.43%, HENLIUS down 3.32%.</p><p>BEONE MEDICINES is a global oncology company focused on developing novel therapies for cancer patients worldwide. Its product portfolio spans hematology and solid tumors, with key marketed products including Brukinsa, Tevimbra, and Pamiparib, alongside a deep pipeline of next-generation candidates.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1177560204","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177560204","pubTimestamp":1790904985,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 2, BEONE MEDICINES fell 6.3% in regular trading, trading at 209.6 HKD/share, with turnover of approximately 105 million HKD.Within the Biotechnology sector where BEONE MEDICINES belongs,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势警报|BEONE MEDICINES常规交易跌6.3%，报209.6港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On October 2, BEONE MEDICINES fell 6.3% in regular trading, trading at 209.6 HKD/share, with turnover of approximately 105 million HKD.Within the Biotechnology sector where BEONE MEDICINES belongs, the overall sector came under broad selling pressure. Among individual stocks, INNOVENT BIO down 5.1%, AKESO down 2.67%, SKB BIO down 4.52%, 3SBIO down 5.43%, HENLIUS down 3.32%.BEONE MEDICINES is a global oncology company focused on developing novel therapies for cancer patients worldwide. Its product portfolio spans hematology and solid tumors, with key marketed products including Brukinsa, Tevimbra, and Pamiparib, alongside a deep pipeline of next-generation candidates.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}